

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

HOPEWELL PHARMA VENTURES, INC.,
Petitioner

v.

MERCK SERONO S.A.,
Patent Owner

Case IPR2023-00480
U.S. Patent No. 7,713,947

**PETITIONER HOPEWELL PHARMA VENTURES, INC.’S
MOTION TO SEAL EXHIBITS 1059, 1060, 1063, 1080, 1084, AND
PETITIONER’S REPLY**

Mail Stop “PATENT BOARD”
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

TABLE OF CONTENTS

I. INTRODUCTION 1

II. GOVERNING RULES AND PTAB GUIDANCE..... 1

III. IDENTIFICATION OF CONFIDENTIAL DOCUMENTS..... 2

 A. Exhibits 1059, 1060, and 1063 3

 B. Exhibits 1080 and 1084 3

 C. Hopewell’s Reply 4

IV. GOOD CAUSE EXISTS FOR SEALING THE CONFIDENTIAL INFORMATION. 4

V. RELIEF REQUESTED..... 6

VI. CONCLUSION 6

I. INTRODUCTION

Pursuant to 37 C.F.R. §§ 42.14 and 42.54, Petitioner Hopewell Pharma Ventures, Inc. (“Hopewell”) respectfully submits this Motion to Seal Exhibits 1059, 1060, 1063, 1080, 1084, and the Petitioner’s Reply (collectively “the Confidential Documents”). The parties have met and conferred regarding the Motion to Seal, as required by 37 C.F.R. § 42.54(a), and Patent Owner Merck Serono, S.A. (“Merck”) has stated it will not oppose this motion.

All of the confidential material submitted in this proceeding belongs to Merck. Good cause to seal exists because Merck has represented to Hopewell that certain information in the Confidential Documents is “highly confidential, competitively sensitive information.” Mot. To Seal And For Entry of Default Protective Order, 2, *Hopewell Pharma Ventures, Inc. v. Merck Serono SA*, IPR2023-00480 (P.T.A.B. Dec. 21, 2023) (“Paper 19”). Hopewell therefore submits this Motion to Seal under the Default Protective Order in this case. *See* Paper 19.

II. GOVERNING RULES AND PTAB GUIDANCE

While under 35 U.S.C. § 316(a)(1), papers filed in an *inter partes* review are generally open and available for access by the public, a party may file a concurrent Motion to Seal to protect public disclosure of certain confidential information, which has the effect of sealing the information at issue pending resolution of the

motion. In determining whether to grant a Motion to Seal, the Board must find “good cause,” 37 C.F.R. § 42.54(a), and “strike a balance between the public’s interest in maintaining a complete and understandable file history and the parties’ interest in protecting truly sensitive information,” Consolidated Trial Practice Guide, November 2019 (“TPG”), 19. The Board identifies confidential information in a manner “consistent with Federal Rule of Civil Procedure 26(c)(1)(G), which provides for protective orders for ... confidential research, development, or commercial information.” TPG, 19.

Based on the procedure set forth in the TPG, Hopewell seeks to prevent the disclosure of sensitive information that Merck has represented is contained in the Confidential Documents.

III. IDENTIFICATION OF CONFIDENTIAL DOCUMENTS

The Confidential Documents at issue here comprise Exhibits 1059, 1060, 1063, 1080, 1084, and Hopewell’s Reply, which quotes and characterizes those exhibits and the exhibits previously filed under seal by Merck (Exhibits 2048, 2049, and 2050). Paper 19, 4–7. Under the terms of the Default Protective Order filed by Merck in this case on December 21, 2023, documents so designated must be filed under seal. Default Protective Order, ¶5(A)(i).

A. Exhibits 1059, 1060, and 1063

Exhibits 1059, 1060, and 1063 are the deposition transcripts of Drs. Nicholas Bodor, Yogesh Dandiker, and Alain Munafo, respectively. Merck designated and marked Exhibits 1059, 1060, and 1063 as “CONFIDENTIAL” under the proposed Default Protective Order in this proceeding. Default Protective Order, ¶5(A)(i)-(ii).

With respect to Exhibit 1059, Merck served a redacted copy identifying the portions of the testimony to which a claim of confidentiality is to be maintained, as required by the terms of the Default Protective Order, Appendix B, Section (d)6. Merck did not indicate why these portions of testimony disclosed confidential protective order material. This redacted copy will be made publicly available. Hopewell only moves to file the unredacted copy of Exhibit 1059 under seal. Default Protective Order, ¶5(A)(ii).

With regard to Exhibits 1060 and 1063 (Dandiker and Munafo deposition transcripts), Merck has agreed to Hopewell to filing Exhibits 1060 and 1063 under seal in their entirety.

B. Exhibits 1080 and 1084

Exhibits 1080 and 1084 are the declarations of Dr. Rodolfo Pinal and Dr. Aaron Miller, respectively. Exhibits 1080 and 1084 cite the Confidential Documents. Merck has agreed to Hopewell filing Exhibits 1080 and 1084 under

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.